AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound according to structural formula (I) or (II):



or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof,

wherein:

the B ring is an aromatic or nonaromatic ring that includes from one to four heteroatoms, wherein

X, Y, and Z are each, independently of one another selected from C, CH, N, NR^{16}, NR^{18}, S or O, provided that X and Y are not both O;

U and T are each, independently of one another, selected from C, or CH ~~or N~~;

~~Z is N or --CH--~~;

A is N or --CR^{2}--;

B is N or --CR^{3}--;

D is N or --CR^{4}--;

E is N or --CR^{5}--;

G is N or --CR^{6}--;

J is N or --CR^{8}--;

K is N or --CR^{8}--;

L is N or --CR^{9}--;

M is N or --CR^{10}--;

R^2 a

nd R^6 are each, independently of one another, selected from the group consisting of hydrogen, halo, ~~fluoro, chloro,~~ C_1-C_{15} alkyl, ~~methyl,~~ substituted C_1-C_{15} alkyl, C_1-C_{15} alkylthio, substituted C_1-C_{15} alkylthio, alkoxy, ~~methoxy, i propoxy,~~ substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, aryl-C_1-C_{15} alkyloxycarbonyl, substituted aryl-C_1-C_{15} alkyloxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, carbamoyl, substituted carbamoyl, halo-C_1-C_{15} alkyl, ~~trifluoromethyl,~~ sulfamoyl, substituted sulfamoyl and silyl ethers, provided that one of R^2 and R^6 is other than hydrogen;

R^3 and R^5 are each, independently of one another, selected from the group consisting of hydrogen, halo, ~~chloro,~~ C_1-C_{15} alkyl, substituted C_1-C_{15} alkyl, C_1-C_{15} alkylthio, substituted C_1-C_{15} alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, aryl-C_1-C_{15} alkyloxycarbonyl, substituted aryl-C_1-C_{15} alkyloxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, cycloheteroalkyl, substituted cycloheteroalkyl, carbamoyl, substituted carbamoyl, halo-C_1-C_{15} alkyl, sulfamoyl and substituted sulfamoyl;

R^4 is selected from the group consisting of hydrogen, halo, C_1-C_{15} alkyl, substituted C_1-C_{15} alkyl, C_1-C_{15} alkylthio, substituted C_1-C_{15} alkylthio, carbamoyl, substituted carbamoyl, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, aryl-C_1-C_{15} alkyloxycarbonyl, substituted aryl-C_1-C_{15} alkyloxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, di-C_1-C_{15} alkylamino, substituted di-C_1-C_{15} alkylamino, halo-C_1-C_{15} alkyl, sulfamoyl and substituted sulfamoyl;

R^7 is --$NR^{11}C(O)R^{12}$;

R^8, R^9, R^{10} and R^{14} are each, independently of one another, hydrogen, halo or fluoro;

R^{11} is hydrogen, or C_1-C_{15} alkyl ~~or methyl~~; and

R^{12} is selected from the group consisting of substituted C_1-C_{15} alkyl, halo-C_1-C_{15} alkyl, ~~halomethyl, dihalomethyl, dichloromethyl,~~ cycloheteroalkyl and substituted cycloheteroalkyl;

R^{16} and R^{18} are each, independently of one another, selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, lower heteroalkyl, substituted lower heteroalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, lower

haloalkyl, ~~monohalomethyl, dihalomethyl, trihalomethyl, trifluoromethyl~~, lower alkylthio, substituted lower alkylthio, lower alkoxy, substituted lower alkoxy, methoxy, substituted methoxy, lower heteroalkoxy, substituted lower heteroalkoxy, cycloalkoxy, substituted cycloalkoxy, cycloheteroalkoxy, substituted cycloheteroalkoxy, lower haloalkoxy, monohalomethoxy, dihalomethoxy, trihalomethoxy, trifluoromethoxy, lower di- or monoalkylamino, substituted lower di- or monoalkylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, phenoxy, substituted phenoxy, aryl-C_1-C_{15} alkyl, substituted aryl-C_1-C_{15} alkyl, aryl-C_1-C_{15} alkyloxy, substituted aryl-C_1-C_{15} alkyloxy, benzyl, benzyloxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heteroaryl-C_1-C_{15} alkyl, substituted heteroaryl-C_1-C_{15} alkyl, heteroaryl-C_1-C_{15} alkyloxy, substituted heteroaryl-C_1-C_{15} alkyloxy, carboxyl, lower alkoxycarbonyl, substituted lower alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aryl-C_1-C_{15} alkyloxycarbonyl, substituted aryl-C_1-C_{15} alkyloxycarbonyl, carbamate, substituted carbamate, carbamoyl, substituted carbamoyl, sulfamoyl, substituted sulfamoyl and a group of the formula -L-R^{17}, where "L" is a linker and R^{17} is cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl.

with the provisos that:

(i) at least one of A, B, D, E, G, J, K, L or M is N;

(ii) no more than one of A, B, D, E or G is N; and

(iii) no more than one of J, K, L or M is N.

2. (Original) The compound of claim 1 in which one of A, B, D, E or G is N and one of J, K, L or M is N.

3. (Original) The compound of claim 1 in which one of A, B, D, E or G is N and none of J, K, L or M is N.

4. (Original) The compound of claim 1 in which none of A, B, D, E or G is N and one of J, K, L or M is N.

5. (Original) The compound of claim 1 in which the B-ring is an oxazole or hydro isomer thereof.

6. (Original) The compound of claim 1 in which the B ring is a thiazole or a hydro isomer thereof.

7. (Original) The compound of claim 1 in which the B ring is an imidazoleor a hydro isomer thereof.

8. (Original) The compound of claim 1 in which the B ring is a triazole or a hydro isomer thereof.

9. (Original) The compound of claim 1 in which the B ring is an oxadiazole or a hydro isomer thereof.

10. (Original) The compound of claim 1 in which the B ring is an isoxazole or a hydro isomer thereof.

11. (Original) The compound of claim 1 in which the B ring is a pyrazole or a hydro isomer thereof.

12. (Original) The compound of claim 1 in which the B ring is a thiadiazole or a hydro isomer thereof.

13. (Original) The compound of any one of claims 1-12 in which R^7 is $--NR^{11}C(O)R^{12}$, wherein R^{11} is hydrogen or methyl and R^{12} is $--CHCl_2$.

14. (Original) The compound of claim 13 in which X is N, Y is O and Z is --CH--.

15. (Currently Amended) The compound of claim 1 ~~any one of claims 1-13~~ in which A is $--CR^2--$, G is $--CR^6--$, R^7 is $--NR^{11}C(O)R^{12}$, where R^{11} is hydrogen or methyl and R^{12} is $--CHCl_2$.

16. (Original) The compound of claim 15 in which B is $--CR^3--$, D is N, E is $--CR^5--$, J is $--CR^{14}--$, K is $--CR^8--$, L is $--CR^9--$, M is $--CR^{10}--$, and R^3, R^5, R^9, R^{10} and R^{14} are each hydrogen.

17. (Original) The compound of claim 16 in which R^8 is fluorine.

18. (Original) The compound of claim 15 in which B is $--CR^3--$, D is $--CR^4--$, E is $--CR^5--$, J is $--CR^{14}--$, K is $--CR^8--$, L is $--CR^9--$, M is N and R^3, R^4, R^5, R^8, R^9 and R^{14} are each hydrogen.

19. (Original) The compound of claim 15 in which B is --CR^3--, D is --CR^4--, E is --CR^5--, J is --CR^{14}--, K is --CR^8--, L is N, M is --CR^{10}-- and R^3, R^4, R^5, R^8, R^{10} and R^{14} are each hydrogen.

20. (Currently Amended) The compound of any one of claims 15-19 in which R^2 and R^6 are each, independently of one another, selected from the group consisting of chloro, fluoro, methyl, triflouromethyl, thiomethyl, methoxy, i-propoxy, N-morpholino and N-morpholinosulfamoyl.

21. (Currently Amended) The compound of any one of claims 15-19 in which R^2 and R^6 are each, independently of one another, selected from the group consisting of chloro, fluoro, methyl, triflouromethyl, methoxy or i-propoxy.

22. (Currently Amended) The compound of any one of claims 15-19 in which R^2 and R^6 are each the same or different halo.

23. (Currently Amended) The compound of any one of claims 15-19 in which X is N, Y is O and Z is --CH--.

24. (Original) The compound of claim 1 in which A is --CR^2--, G is --CR^6-- and R^7 is --$NR^{11}C(O)R^{12}$, where R^{11} is hydrogen or methyl and R^{12} is --CH_2I.

25. (Original) The compound of claim 24 in which R^2 and R^6 are each, independently of one another, selected from the group consisting of chloro, fluoro, methyl, triflouromethyl, thiomethyl, methoxy, i-propoxy, N-morpholino and N-morpholinosulfamoyl.

26. (Original) The compound of claim 24 in which R^2 and R^6 are each, independently of one another, selected from the group consisting of chloro, fluoro, methyl, triflouromethyl, methoxy and i-propoxy.

27. (Original) The compound of claim 24 in which R^2 and R^6 are each the same or different halo.

28. (Original) The compound of claim 24 in which X is N, Y is O and Z is --CH--.

29. (Original) The compound of claim 1 in which A is --CR^2--, B is --CR^3--, R^7 is --$NR^{11}C(O)R^{12}$, where R^{11} is hydrogen or methyl and R^{12} is --$CHCl_2$.

30. (Original) The compound of claim 29 in which D is --CR^4--, G is --CR^6--, E is --CR^5--, J is --CR^{14}--, K is --CR^8--, L is --CR^9--, M is N and R^4, R^5, R^6, R^8, R^9 and R^{14} are each hydrogen.

31. (Original) The compound of claim 29 in which D is --CR^4--, G is --CR^6--, E is --CR^5--, J is --CR^4--, K is --CR^8--, L is N, M is --CR^{10}-- and R^4, R^5, R^6, R^8, R^{10} and R^{14} are each hydrogen.

32. (Original) The compound of any one of claims 29-31 in which R^2 is chloro, fluoro, methyl, triflouromethyl, thiomethyl, methoxy, i-propoxy, N-morpholino or N-morpholinosulfamoyl and R^3 is chloro, fluoro, methyl, triflouromethyl or methoxy

33. (Original) The compound of any one of claims 29-31 in which R^2 is chloro, fluoro, methyl, triflouromethyl or methoxy and R^3 is chloro, fluoro or triflouromethyl.

34. (Original) The compound of any one of claims 29-31 in which R^2 and R^3 are each the same or different halo.

35. (Original) The compound of any one of claims 29-31 in which X is N, Y is O and Z is --CH--.

36. (Original) The compound of claim 1 in which A is --CR^2--, G is --CR^6-- and R^2 and R^6 are each identical, provided that R and R^6 are not hydrogen.

37. (Original) The compound of claim 1 in which A is --CR^2--, B is --CR^3-- and R^2 and R^3 are each identical, provided that R and R^3 are not hydrogen.

38. (Original) The compound of claim 1 in which B is --CR^3--, E is --CR^5-- and R^3 and R^5 are each identical, provided that R^3 and R^5 are not hydrogen.

39. (Original) The compound of claim 1 in which B is --CR^3--, D is --CR^4--, E is --CR^5--, J is --CR^{14}--, K is --CR^8-- and R^3, R^4, R^5, R^8 and R^{14} are each hydrogen.

40. (Original) The compound of claim 1 in which -D is --CR^4--, E is --CR^5--, G is CR^6, J is --CR^{14}--, K is --CR^8-- and R^4, R^5, R^6, R and R^{14} are each hydrogen.

41. (Currently Amended) The compound of claim 1 which has the structural formula (Ia), (Ib), (Ic), (Id) or (Ie):

(Ia)



(Ib)



(Ic)



(Id)



(Ie)



or a pharmaceutically acceptable salts, hydrates or solvates thereof, wherein X, Y, R^2, R^6, R^{11} and R^{12} are as previously defined for claim 1 and --- represents a single or double bond.

42. (Currently Amended) The compound of claim 41 in which R^{11} is hydrogen, R^{12} is dichloromethyl and R^2 and R^6 are each, independently of one another, selected from the group consisting of ~~halo,~~ fluoro, chloro, trifluoromethyl and methoxy.

43. (Currently Amended) The compound of claim 1 which has the structural formula (If):



or a pharmaceutically acceptable salts, hydrates or solvates thereof, wherein R^2, R^3, R^4, R^5, R^6, R^8, R^9, R^{11}, R^{12} and R^{14} are as previously defined for claim 1 and subject to the same provisos and --- represents a single or double bond.

44. (Currently Amended) A compound ~~selected from the group of compounds depicted in FIG. 1,~~ which inhibits HCV replication and/or proliferation ~~with an IC_{50} of 100 μM or less,~~ as measured in an in vitro ~~assay~~ assay, the compound selected from the group consisting of



1



3



5



7



9



11



13



17



19



21



27



29



31



33



35



37



39



43



45



47



49



51



53



57



59



61



63

and

45. (Canceled)

46. (Withdrawn) A method of inhibiting replication or proliferation of a hepatitis C ("HC") virion, comprising the step of contacting a HC virion with an amount of a compound of any one of claims 1-12 effective to inhibit replication of the HC virion.

47. (Withdrawn) The method of claim 46 which is practiced in vitro.

48. (Withdrawn) The method of claim 46 which is practiced in vivo.

49. (Withdrawn) A method of treating or preventing an HCV infection, comprising the steps of administering to a subject an effective amount of a compound of any one of claims 1-12 effective to treat or prevent an HCV infection.

50. (Withdrawn) The method of claim 49, wherein the subject is a human.

51. (Withdrawn) The method of claim 49, wherein the compound is administered in an amount of 0.1 mg/kg to 200 mg/kg.

52. (Withdrawn) The method of claim 49, wherein the compound is administered in an amount of 10 mg/kg to 100 mg/kg.

53. (Withdrawn) The method of claim 49, wherein the compound is administered orally.

54. (Withdrawn) The method of claim 49, wherein the compound is administered by injection.

55. (Withdrawn) The method of claim 49, wherein the compound is selected from the group of compounds depicted in FIG. 1 and which inhibits HCV replication and/or proliferation with an IC_{50} of about 10 μM or less, as measured in an in vitro assay.

56. (Withdrawn) The method of claim 49 which is practiced therapeutically in a subject having an HCV infection.

57. (Withdrawn) The method of claim 49 which is practiced prophylactically in a subject at risk of developing an HCV infection.

58. (Original) A composition comprising a compound of any one of claims 1-12 and a pharmaceutically acceptable vehicle.